Navigation Links
B-Cell Biologic Therapy Could Revolutionize Rheumatoid Arthritis Treatment

Biologic therapy directed at B-cells could turn out be more effective in the treatment of rheumatoid arthritis, a chronic inflammatory disease arising out of an auto immune disorder.//

An international study conducted on Rituximab, a form of biologic therapy for treatment of rheumatoid arthritis has been found to achieve remission in rheumatoid arthritis patients who exhibit resistance to conventional DMARDs. The effect, independent of steroid administration is seen despite the variability in the dosage of the drug.

Drugs aimed at suppressing inflammation-provoking cytokines--specifically those linked to T-cells--have improved the treatment of rheumatoid arthritis (RA). Still, the frequency of remission achieved by these biologic agents remains below 50 percent. To increase the success rate of biologic therapy for RA patients, researchers have honed in on a new target: the B cell.

Rituximab, a biologic agent that selectively depletes B cells, has been successfully used to treat non-Hodgkin's lymphoma. It has also been shown to improve disease symptoms for RA patients, when injected at aggressive levels for a two-week period. To investigate this biologic's potential long-term therapeutic value, an international team of scientists set out to compare the effectiveness and safety of different rituximab doses over a 24-week period, with and without steroids. Their study focused on 465 RA patients with moderate to severe symptoms resistant to disease-modifying antirheumatic drugs (DMARDs), including other biologics. The results, featured in the May 2006 issue of Arthritis & Rheumatism.

Drawn from outpatient populations in California, Texas, Arizona, Switzerland, Sweden, Poland, and England, the subjects were randomly divided into nine treatment groups. Three groups received a 1,000-mg. dose of rituximab--two infusions two weeks apart--with either intravenous steroid, oral steroid, or placebo. Three groups received a 50 0 mg. dose of rituximab--two infusions two weeks apart--with either intravenous steroid, oral steroid, or placebo. Three groups received a placebo with either intravenous steroid, oral steroid, or another placebo. All subjects received the DMARD methotrexate (MXT). All subjects were evaluated every four weeks for changes in the Disease Active Score (DAS), a 28-joint assessment for swelling and tenderness, as well as for overall disease improvement, with the goal of meeting the American College of Rheumatology (ACR) 20 percent improvement criteria.

At the 24-week culmination, 54 percent of the subjects in three rituximab 1,000 mg. X 2 groups and 55 percent of the subjects in the three rituximab 500 mg. X 2 groups had achieved the desired ACR20 response, compared with 28 percent of the subjects in the three placebo groups. The different dosages of rituximab did not have a statistically significant impact on the odds of achieving an ACR20 response, and analyses of the proportions of patients who achieved higher ACR improvement scores--50 percent and 70 percent--showed similar patterns. Changes in DAS28 at week 24 reflected the ACR response findings, as did the subjects reports of relief from joint pain and stiffness. What's more, subjects in the rituximab groups showed gains toward disease remission earlier in the course of treatment than subjects in the placebo group.

Steroids, whether received intravenously or orally, showed no significant correlation with disease improvement scores among the rituximab groups. Intravenous steroid, however, showed a positive correlation to improved tolerability during the first rituximab infusion in both dosage groups. Overall, adverse events associated with rituximab were mild and easily managed. Headache was the most common complaint.

Confirming the role of B cells in the inflammatory processes behind RA, this study demonstrates the effectiveness and safety of a unique biologic therapy, in moderat e doses and independent of steroids. Yet, as its leading author, Dr. Paul Emery, notes, further studies are needed before applying the results to the routine treatment of RA patients. 'Both doses of rituximab explored in this study warrant further differential exploration and longer-term follow-up,' he stresses.


'"/>




Related medicine news :

1. Smallpox as Biological Weapons?
2. Biologicals Transfer Proposal between US and Indian Biotechnology
3. Novel Biological Pacemaker Under Construction for Weak Hearts
4. Biologically Women Are More Vulnerable To HIV Infection
5. Biological Clock Could Be Re-Set: Study
6. Gold Nanoparticles Are Good Detectors Biological Toxins
7. Sunglasses Can Really Pull a Fast One on the Biological Clock, and Set a Lag in the Build Up Of Jet Lag
8. Can Men Gauge Biological Paternity Accurately
9. Biological Basis for Homosexuality
10. Biological Basis Behind a Couch Potato
11. Artificial Light May Damage Biological Clock In Premature Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce ... a longtime supporter of the event. , "We are pleased that KLS Martin is ... Havlik, 2017 ACPA President. "KLS Martin has a long track record of support of ...
(Date:2/23/2017)... ... , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North ... month of February, patients who visit Hamlin Dental Group will receive a ticket for ... at the Cheesecake Factory. , Tickets are available for routine dental visits and ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information ... National Institute for Health and Care Excellence (NICE) framework. The agreement ... Health Service (NHS) to search, order and purchase medical and healthcare-related content through ...
(Date:2/23/2017)... ... 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice ... a 2017 Top Patient Rated Henderson Dentist by Find Local Doctors earlier ... physicians and dentists who have earned high ratings and superior patient reviews from multiple ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Autism ... to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis and ... global Autism Spectrum Disorder market. The research answers the following ... marketed for Autism Spectrum Disorder and their clinical attributes? How are ...
(Date:2/23/2017)... MINNEAPOLIS , Feb. 23, 2017  Cogentix Medical, ... manufactures and markets innovative proprietary products for the urology ... and fiscal year ended December 31, 2016 before the ... The Company will host a conference call and ... on Thursday, March 9, 2017 at 11:00 a.m. Eastern ...
Breaking Medicine Technology: